The Effect of an Adhesive Overlay on the Delivery of Contraceptive Hormones From ORTHO EVRA® in Healthy Women
Phase 1
Completed
- Conditions
- Healthy Volunteers
- First Posted Date
- 2012-02-20
- Last Posted Date
- 2013-03-20
- Target Recruit Count
- 54
- Registration Number
- NCT01535820
A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)Drug: B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2012-08-29
- Target Recruit Count
- 64
- Registration Number
- NCT01518712
A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency
- First Posted Date
- 2011-12-20
- Last Posted Date
- 2014-02-28
- Target Recruit Count
- 6
- Registration Number
- NCT01495910
Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma
Phase 2
Withdrawn
- Conditions
- Asthma
- Interventions
- Drug: PlaceboDrug: JNJ-39758979 30 mg/dDrug: JNJ-39758979 100 mg/dDrug: JNJ-39758979 300 mg/d
Effect of Dose on the Pharmacokinetics of OROS Hydromorphone Under Fasted Conditions in Healthy Taiwanese Participants
Phase 1
Completed
- Conditions
- Healthy Volunteers
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2012-11-16
- Target Recruit Count
- 29
- Registration Number
- NCT01487512
A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)Drug: B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2013-05-06
- Target Recruit Count
- 64
- Registration Number
- NCT01454622
A Study to Investigate How JNJ-38518168 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: JNJ-38518168 / MTX
- First Posted Date
- 2011-10-13
- Last Posted Date
- 2013-05-06
- Target Recruit Count
- 20
- Registration Number
- NCT01450982
A Study to Investigate How JNJ-39758979 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: JNJ-39758979 / MTX
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2013-03-13
- Target Recruit Count
- 21
- Registration Number
- NCT01442545
A Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Canagliflozin/Probenecid
- First Posted Date
- 2011-09-02
- Last Posted Date
- 2012-02-17
- Target Recruit Count
- 14
- Registration Number
- NCT01428284
A Study to Evaluate the Effects of Rifampin on Single-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2013-05-06
- Target Recruit Count
- 14
- Registration Number
- NCT01395927
© Copyright 2025. All Rights Reserved by MedPath